Gene-panel sequencing and the prediction of breast-cancer risk.
about
Multigene testing of moderate-risk genes: be mindful of the missensePALB2: research reaching to clinical outcomes for women with breast cancerManaging breast cancer in younger women: challenges and solutionsGenomics of Cancer and a New Era for Cancer PreventionIdentification et prise en charge des femmes ayant des antécédents familiaux de cancer du sein: Guide pratique à l’intention des médecinsIdentification and management of women with a family history of breast cancer: Practical guide for cliniciansPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSEndometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.Developing and evaluating polygenic risk prediction models for stratified disease prevention.Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer.Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patientsThe contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriersA monograph proposing the use of canine mammary tumours as a model for the study of hereditary breast cancer susceptibility genes in humansPayer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.Counselling framework for moderate-penetrance cancer-susceptibility mutations.Rates of BRCA1/2 mutation testing among young survivors of breast cancerNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-MakingIdentification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscapeCharacterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control studySEOM clinical guidelines in Hereditary Breast and ovarian cancer.First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patientsIntegrating population variation and protein structural analysis to improve clinical interpretation of missense variation: application to the WD40 domain.Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohortGenetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era.Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trialPathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testingThe Role of Constitutional Copy Number Variants in Breast Cancer.Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-UpOutcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
P2860
Q24658557-C6E877C5-1FE1-4957-A7AD-105A8D689223Q26751309-9DE23CD4-769E-47AF-90AC-7B2C5950206FQ26771184-62AD7D7F-7B87-4760-B972-F6EDAD423775Q26779113-B8684DE7-5AD9-45AD-9473-905551761C35Q28077316-C7F0F36E-E3A3-474F-AEF2-C4E993A3E2D9Q28077578-ED0C5949-6A11-40AF-BB46-640BA5A29768Q28584533-81ED6D47-35E0-44C7-BC0E-4FCA39FC3659Q30234614-5EF91CE1-996A-4019-8F5E-866DD42F3CB1Q30238753-9CC1E695-85B7-41A4-BE67-5F4BD036F34CQ30251440-B45AF271-9B62-47CE-9FA4-7B5DF9BCDAA8Q33606741-065A9340-A3F1-4479-93F9-01DEC69CDE78Q33618262-394CA447-587E-4869-8C17-2D991964154BQ33784408-FFC7638A-3026-44B9-BCD4-1756A7C0A8D8Q33823472-A62215C1-0368-4FE7-87B6-BE927628ACFEQ33845912-A1F6D823-A8B0-4A46-A105-A861A9A038FBQ33900845-8B79E965-CBE5-406A-A82A-8FFC77C463B0Q33911135-9D28CA5D-2CF5-4395-8047-706520443B10Q33923031-638F999B-B096-4119-8668-075086D7F513Q34550417-E7D6C808-27E1-449A-8698-B90913C475ACQ36044085-D8D1412B-67A7-417B-A7F4-4BA688490878Q36098651-322C34C3-C6DA-44A6-981A-79538C0BB5E4Q36101775-E1949BDA-0E03-437A-8DB2-447A0B1CCE04Q36208014-2BB9D69E-5D87-4365-99DA-0F0417F2C9D8Q36239238-A105236D-55A7-4CA3-BA31-AC32A632C13BQ36286700-58C5FC5B-5E9F-4537-8933-1A973797E18DQ36400244-07B69B68-AA78-45AB-B684-DF501F8D0ADCQ36546414-158422F6-D398-4F75-915E-553801BA8FD8Q36562289-32B4BA54-4B63-4DB4-A93E-FBCC7504BF2DQ36581402-5E233A77-C9B9-45D6-876F-EB6E92FBF342Q36808649-7F31D1F1-6643-47D6-9BAD-B35B2EC1C4FBQ36849670-2686667C-3E57-4B1E-B56C-793F9E144E90Q36915151-482978A3-1836-4043-A363-2550D39E6D91Q37011929-3FF5930D-19F6-4A85-AB0B-40B9D2EB0A08Q37025837-C5FE2FB8-D6FB-4FFF-8BB4-0B96EB6A128BQ37079859-EEC043BE-26E7-4ADE-9DEF-6E97966D043BQ37138925-CA0C1308-A8EF-4BDB-B5F4-EA449BB88B7BQ37176931-E991C9A7-EA6B-4EEA-80AB-5C542ED813D4Q37200793-EF0BBAC2-DAE1-47CD-B549-824CCA666CFDQ37234775-3A445F07-E553-485D-90E2-775D0BA601D8Q37267678-9E14B3A4-AE23-4BDF-96C6-E9AEA5AAC4DA
P2860
Gene-panel sequencing and the prediction of breast-cancer risk.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Gene-panel sequencing and the prediction of breast-cancer risk.
@ast
Gene-panel sequencing and the prediction of breast-cancer risk.
@en
type
label
Gene-panel sequencing and the prediction of breast-cancer risk.
@ast
Gene-panel sequencing and the prediction of breast-cancer risk.
@en
prefLabel
Gene-panel sequencing and the prediction of breast-cancer risk.
@ast
Gene-panel sequencing and the prediction of breast-cancer risk.
@en
P2093
P2860
P50
P356
P1476
Gene-panel sequencing and the prediction of breast-cancer risk.
@en
P2093
David E Goldgar
Marc Tischkowitz
Sean V Tavtigian
P2860
P304
P356
10.1056/NEJMSR1501341
P407
P50
P577
2015-05-27T00:00:00Z